AnGes, Inc. (TYO:4563)

Market Cap	24.68B
Revenue (ttm)	699.00M
Net Income (ttm)	-27.55B
Shares Out	333.51M
EPS (ttm)	-104.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,907,800
Average Volume	7,062,985
Open	72.00
Previous Close	71.00
Day's Range	70.00 - 74.00
52-Week Range	45.00 - 98.00
Beta	0.90
RSI	64.45
Earnings Date	Aug 8, 2025

About HashiCorp

AnGes, Inc. engages in the research and development of gene-based medical products. It develops HGF gene therapy product for the treatment of ischemic diseases; NF-κB Decoy Oligo DNA for chronic discogenic lumber back pain; and DNA vaccines for the treatment of hypertension and cervical intraepithelial neoplasia, as well as intranasal formulation of the COVID-19 vaccine. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 55
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4563

Financial Performance

In 2024, AnGes's revenue was 643.00 million, an increase of 323.03% compared to the previous year's 152.00 million. Losses were -28.13 billion, 278.2% more than in 2023.